InvestorsHub Logo
icon url

CTMedic

04/23/21 6:58 AM

#161029 RE: name #161027

Name,

Thank you for sharing those with links with us.

In addition to acute severe and critical covid, Leronlimab will be needed to treat PACS/LH/CFS-ME.

Personally, I was dismissive of LH/PACS study when first I learned of it. Only upon reading more widely did I begin to appreciate the impact, both in lives disrupted (ruined?) and economic impact, from LH covid. Without effective treatment for PACS, we will have a generation of disability.

Covid 19 has already caused three times the economic damage as the 2008 recession, with no signs of abating.

https://www.weforum.org/agenda/2020/09/an-economist-explains-what-covid-19-has-done-to-the-global-economy/

Leronlimab will continue to be denigrated by those who benefit from the narrative of "lerosaline", "fraud", "failure" and so on.

At some point, it is just hot air and noise. That is, insubstantial and ephemeral.

Leronlimab is here and change will follow.

GLTU
icon url

Emergcy

04/23/21 7:10 AM

#161030 RE: name #161027

I feel the news about LL support for research is awful news for CYDY. Why?

1) like for COVID, the BP will smell the big money
2) like for Wrap speed, BP will get the money, and CyDy not one Penny
3) Like for COVID, FDA will start to slow us down incredibly

We had a chance as long as it was an unrecognized niche and BP wasn't interested, but now the game starts from the beginning.